Dr. Muhit Rana is a panel examiner of the National Institutes of Health (NIH), and also served as the Principal Scientist in the R&D department at Giner, Inc., where he pioneers cutting-edge research in biosensors, nucleic acid nanotechnology, and point-of-care diagnostics. Holding a Ph.D., Dr. Rana is recognized for his expertise in developing innovative tools for biomarker detection, particularly in the realm of liquid biopsy and theranostics. His work is critical in advancing non-invasive cancer diagnostics and enabling rapid, multiplexed detection of disease biomarkers through nanotechnology.

Dr. Rana’s influential publications include high-impact studies on DNA-capped gold nanoparticles as peroxidase mimics, simultaneous detection of cancer-related oncomiRs using nanographene oxide, and the development of universal sensor arrays for selective identification using two-dimensional nanoparticles. His research contributions, frequently cited in the scientific community, demonstrate a profound commitment to improving diagnostic sensitivity and specificity across various platforms.

With a robust portfolio of articles in leading journals such as Analytical Chemistry, ACS Applied Materials & Interfaces, and Chemical Science, Dr. Rana's innovative approaches are at the forefront of diagnostic technology. His recent work on the visual detection of opioid metabolites in wastewater and the specific detection of oxytocin in saliva exemplifies his dedication to addressing critical challenges in healthcare and environmental monitoring.

Erik E. Augspurger is a Researcher at The RNA Institute, University at Albany, and Albany Medical College’s Sports Medicine Department, specializing in nano-bio medicine, DNA nanotechnology, and sports science. His research focuses on nucleic acid-based biosensing using hybridization chain reactions, molecular logic gates, and programmable nanoprobes for chemical and biological detection. He also investigates musculoskeletal development, neurocognitive assessment, and neck strength in youth athletes across sports disciplines. By integrating DNA nanotechnology, bioengineering, and applied sports medicine, Augspurger advances precision diagnostics, molecular sensing strategies, and evidence-based approaches to athlete health, performance, and injury prevention.

Keywords: nano-bio medicine, DNA nanotechnology, hybridization chain reaction, molecular logic gates, biosensing, programmable nanoprobes, sports medicine, youth athletes, neurocognitive assessment, musculoskeletal development.

Dr. Md Nafiujjaman is a prominent researcher in nanomedicine, theranostics, and drug delivery systems. As a Research Associate at Michigan State University, his work focuses on developing cutting-edge contrast agents and nanotechnology-driven therapeutic strategies for precision medicine. Dr. Nafiujjaman has over 20 high-impact publications and 1,700 citations, reflecting his contributions to advanced biomedical applications such as graphene quantum dots, photo-chemo theranostics, and exosome-based diagnostics. His research bridges molecular nanotechnology with clinical innovation, offering transformative solutions in imaging, cancer therapy, and biomarker discovery. Recognized globally, Dr. Nafiujjaman’s work advances the field of nanomedicine and translational healthcare.

Dr. Md Nurunnabi is a bioengineering researcher with appointments at UM, UTEP, Harvard, and KNUT, specializing in drug delivery, biomaterials, and nanomedicine. His work focuses on developing graphene- and quantum dot-based nanocarriers, hyaluronic acid nanogels, and mucoadhesive systems for targeted cancer therapy, photodynamic therapy, and controlled drug release. He integrates nanomaterials, polymeric modification, and biosensing for diagnostic and therapeutic applications, emphasizing biocompatibility and in vivo efficacy. Dr. Nurunnabi’s research advances precision medicine through innovative biomaterials and delivery platforms, combining bioengineering, nanotechnology, and pharmacology to enhance disease treatment and biomedical imaging strategies.

Keywords: bioengineering, drug delivery, biomaterials, graphene nanoparticles, quantum dots, nanogels, photodynamic therapy, cancer therapy, controlled release, biomedical imaging.

ORCID: https://orcid.org/0000-0003-4457-3401

Md. Shariful Islam is a Professor in the Department of Veterinary and Animal Sciences at the University of Rajshahi, Bangladesh. His research spans nanotechnology, materials science, tissue and biomedical engineering, and poultry science, with a strong emphasis on sustainable and antibiotic-free animal production. He has made significant contributions to nanoparticle synthesis, photocatalysis, cancer cell targeting, and biomaterials for tissue engineering, alongside impactful work in poultry nutrition, health, and farm sustainability. Prof. Islam has published extensively in high-impact journals, and his interdisciplinary research bridges advanced materials science with veterinary, biomedical, and agricultural applications.

Research Areas: Nanotechnology, Poultry Science, Antibiotic-Free Animal Production, Biomaterials & Tissue Engineering, Photocatalytic Nanoparticles, Sustainable Livestock Systems

Dr. Mustafa Balcioglu is a Principal Scientist in R&D at Natera, specializing in liquid biopsy, circulating tumor DNA (ctDNA), and noninvasive cancer diagnostics. His research focuses on ultrasensitive detection of residual and metastatic cancers through multiplexed assays, nanomaterial-based biosensing, and programmable graphene and gold nanoparticle platforms. He has advanced technologies for early detection of cancer recurrence, oncomiR profiling, and molecular residual disease monitoring. Dr. Balcioglu’s work integrates nanotechnology, bioengineering, and next-generation sequencing to develop scalable, patient-specific diagnostics, contributing to precision oncology and personalized medicine.

Keywords: liquid biopsy, circulating tumor DNA, ctDNA, nanomaterials, graphene, gold nanoparticles, biosensing, oncomiRs, cancer diagnostics, precision medicine.

Competing financial interests: This editor has no conflict of interest.